Mumbai, Feb 12: Cipla Ltd shares traded lower in today’s session, slipping 0.97% to ₹1,336.80, as investors reacted to rising cost pressures despite continued revenue expansion and stable operational growth.
For FY25, Cipla reported total revenue of ₹2.00 lakh crore, marking steady growth driven by strong performance across domestic formulations, export markets, and specialty portfolio. Net revenue from operations stood at ₹1.90 lakh crore, reflecting consistent demand and diversified geographic contribution.
However, total expenditure rose sharply to ₹1.38 lakh crore, primarily due to higher raw material costs and operational spending. Cost of materials consumed increased significantly, while inventory adjustments and procurement dynamics also impacted margins, keeping profitability under pressure.
Market participants are closely tracking margin trajectory, product mix, and global market performance, as these remain critical for pharma sector valuations. While the company’s long-term fundamentals remain supported by strong pipeline, respiratory leadership, and export strength, near-term stock movement may stay sensitive to margin recovery and cost normalization trends.
Traders are watching volume strength and key support levels, while investors focus on earnings sustainability, operating margin recovery, and growth visibility in regulated markets.
